Ann: First Patient Recruited to ACCENT Trial in Pancreatic Cancer, page-30

The beauty of this trial is that it should be super easy to recruit patients and results one way or the other should therefore be delivered in short time. AMP945 has been given to healthy volunteers with NO significant side effects. There are unfortunately plenty of new pancreatic cancer diagnoses every month. Offering these people an adjunct medication prior to starting standard therapy they would receive anyway, with excellent theoretical basis to suggest it might improve their dire predicament, will be a no brainer to take part. I have other biotech investments where there is persisting difficulties recruiting patients and consequently delayed timelines, cost over runs, further capital raisings and dilution and consequently flagging share price.
share price performance here clearly poor since I initially took a position close to 30c but I have been topping up and averaging down
hoping and expecting we have seen a bottom base, chart not yet turned but all this press might provide impetus